Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on February 24, 2009
JNCI Journal of the National Cancer Institute 2009 101(5):281; doi:10.1093/jnci/djp057
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/5/281-c    most recent
djp057v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

MEMO TO THE MEDIA

Goserelin Improves Long-Term Survival in Premenopausal Women with Early Breast Cancer

The first 10% of the full text of this article appears below.

Goserelin, a lutenizing hormone-releasing hormone agonist, reduces the long-term risk of disease recurrence and deaths in premenopausal women with early breast cancer who did not take tamoxifen, according to trial data reported in the February 24 online issue of . . . [Full Text of this Article]

Citation:

Contact:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
Allan Hackshaw, Michael Baum, Tommy Fornander, Bo Nordenskjold, Antonio Nicolucci, Kathryn Monson, Sharon Forsyth, Krystyna Reczko, Ulla Johansson, Helena Fohlin, Miriam Valentini, and Richard Sainsbury
J Natl Cancer Inst 2009 101: 341-349. [Abstract] [Full Text] [PDF]